NEW YORK (360Dx) – The US Food and Drug Administration has given Guardant Health an investigational device exemption approval to provide genomic testing for a cancer drug currently under development.

Guardant is providing testing for a clinical trial of the small molecule, c-Met kinase inhibitor called tepotinib being developed by Merck KGaA, which operates as EMD Serono in the US and Canada. Merck is using Guardant's liquid biopsy test Guardant360 CDx to identify patients with Met exon 14 skipping alterations who may qualify for the ongoing Phase II tepotinib trial.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

The New York City medical examiner is overseeing an effort to identify missing persons using DNA, according to the Associated Press.

Nobel laureate Günter Blobel has died at 81, the New York Times reports.

In PNAS this week: mouse model of genetically induced emphysema, gene expression signatures of circulating melanoma cells, and more.

Technology Review reports that 2017 was the year of consumer genetic testing and that it could spur new analysis companies.